Home  »  Technologies   »  Clovis Oncology Inc. (NASDAQ:CLVS) Could Really Ri...

Clovis Oncology Inc. (NASDAQ:CLVS) Could Really Rise To $2.00 In 12 Months, According To Analysts.

In last trading session, Clovis Oncology Inc. (NASDAQ:CLVS) saw 2.32 million shares changing hands with its beta currently measuring 0.37. Company’s recent per share price level of $0.34 trading at $0.01 or 2.32% at ring of the bell on the day assigns it a market valuation of $48.03M. That closing price of CLVS’s stock is at a discount of -902.94% from its 52-week high price of $3.41 and is indicating a premium of 32.35% from its 52-week low price of $0.23. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.86 million shares which gives us an average trading volume of 3.97 million if we extend that period to 3-months.

For Clovis Oncology Inc. (CLVS), analysts’ consensus is at an average recommendation of a Sell while assigning it a mean rating of 3.50. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.41 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Clovis Oncology Inc. (NASDAQ:CLVS) trade information

Upright in the green during last session for gaining 2.32%, in the last five days CLVS remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $0.34 price level, adding 9.28% to its value on the day. Clovis Oncology Inc.’s shares saw a change of -87.45% in year-to-date performance and have moved -3.11% in past 5-day. Clovis Oncology Inc. (NASDAQ:CLVS) showed a performance of -67.31% in past 30-days. Number of shares sold short was 31.49 million shares which calculate 14.11 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $2.00 to the stock, which implies a rise of 83.0% to its current value. Analysts have been projecting $2.00 as a low price target for the stock while placing it at a high target of $2.00. It follows that stock’s current price would drop -488.24% in reaching the projected high whereas dropping to the targeted low would mean a loss of -488.24% for stock’s current value.

Clovis Oncology Inc. (CLVS) estimates and forecasts

Statistics highlight that Clovis Oncology Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -49.22% of value to its shares in past 6 months, showing an annual growth rate of 27.31% while that of industry is 4.40. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 26.80% in the current quarter and calculating 18.70% increase in the next quarter. This year revenue growth is estimated to fall -10.00% from the last financial year’s standing.

3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $33.22 million for the same. And 3 analysts are in estimates of company making revenue of $34 million in the next quarter that will end on Dec 2022.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 24.10% during past 5 years.

CLVS Dividends

Clovis Oncology Inc. is more likely to be releasing its next quarterly report between February 21 and February 27 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Clovis Oncology Inc. (NASDAQ:CLVS)’s Major holders

Insiders are in possession of 1.43% of company’s total shares while institution are holding 30.65 percent of that, with stock having share float percentage of 31.10%. Investors also watch the number of corporate investors in a company very closely, which is 30.65% institutions for Clovis Oncology Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at CLVS for having 11.22 million shares of worth $20.2 million. And as of Jun 29, 2022, it was holding 7.77% of the company’s outstanding shares.

The second largest institutional holder is Millennium Management Llc, which was holding about 5.4 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 3.74% of outstanding shares, having a total worth of $9.72 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 4.08 million shares of worth $7.34 million or 2.82% of the total outstanding shares. The later fund manager was in possession of 1.76 million shares on Jun 29, 2022, making its stake of worth around $3.16 million in the company or a holder of 1.22% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts